Unlocking the Potential of Organopalladium Complexes for High-Grade Serous Ovarian Cancer Therapy

Thomas Scattolin,Enrico Cavarzerani,Dario Alessi,Matteo Mauceri,Eleonora Botter,Giovanni Tonon,Isabella Caligiuri,Ombretta Repetto,Urska Kamensek,Simona Kranjc Brezar,Maria Dalla Pozza,Stefano Palazzolo,Maja Cemazar,Vincenzo Canzonieri,Nicola Demitri,Steven Patrick Nolan,Gilles Gasser,Fabiano Visentin,Flavio Rizzolio

DOI: https://doi.org/10.26434/chemrxiv-2024-bd942

2024-05-23

Abstract:High-Grade Serous Ovarian Cancer (HGSOC) is the most common and lethal subtype of ovarian cancer, known for its high aggressiveness and extensive genomic alterations. Typically diagnosed at an advanced stage, HGSOC presents formidable challenges in drug therapy. The limited efficacy of standard treatments, development of chemoresistance, scarcity of targeted therapies, and significant tumor heterogeneity render this disease incurable with current treatment options, highlighting the urgent need for novel therapeutic approaches to improve patient outcomes. In this study we report a straightforward and stereoselective synthetic route to novel Pd(II)-vinyl and -butadienyl complexes bearing a wide range of monodentate and bidentate ligands. Most of the synthesized complexes exhibited good to excellent in vitro anticancer activity against ovarian cancer cells. Particularly promising is the water-soluble complex bearing two PTA (PTA = 1,3,5-triaza-7-phosphaadamantane) ligands and the Pd(II)-butadienyl fragment. This compound combines excellent cytotoxicity towards cancer cells with substantial inactivity towards non-cancerous ones. This derivative was selected for further studies on ex vivo tumor organoids and in vivo mouse models, which demonstrate its remarkable efficacy with surprisingly low collateral toxicity even at high dosages. Moreover, this class of compounds appears to operate through a ferroptotic mechanism, thus representing the first such example for an organopalladium compound.

Chemistry

What problem does this paper attempt to address?

The paper aims to address the challenges in the treatment of High-Grade Serous Ovarian Cancer (HGSOC). HGSOC is the most common and lethal subtype of ovarian cancer, known for its high invasiveness and extensive genomic alterations. Typically diagnosed at an advanced stage, HGSOC faces significant challenges in drug treatment. The effectiveness of standard treatment methods is limited, and the emergence of chemotherapy resistance, lack of targeted therapies, and high tumor heterogeneity make this disease difficult to cure. Therefore, there is an urgent need to develop new therapeutic strategies to improve patient prognosis.

The paper reports a simple and stereoselective synthetic route to prepare a series of Pd(II)-vinyl and Pd(II)-butadienyl complexes containing different monodentate and bidentate ligands. Most of these complexes exhibit good in vitro anticancer activity, particularly the water-soluble complexes containing two PTA (1,3,5-triaza-7-phosphaadamantane) ligands and Pd(II)-butadiene fragments. This compound shows significant cytotoxicity against cancer cells while being almost inactive against non-cancer cells. Further studies indicate that this derivative demonstrates significant efficacy in ex vivo tumor organoids and in vivo mouse models, with extremely low side effects even at high doses. Additionally, this class of compounds appears to act through the mechanism of ferroptosis, marking the first discovery of organopalladium compounds functioning via this mechanism.